Given the inconsistent results obtained with the concurrent use of EGFR TKIs and cranial radiotherapy [24–27], the optimal management of patients with EGFR mutant NSCLC with brain metastasis remains to be determined. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.